Article
KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Jan 2013
Webster Jennifer, Kauffman Tia L, Feigelson Heather Spencer, Pawloski Pamala A, Onitilo Adedayo A, Potosky Arnold L, Cross Deanna, Meier Paul R, Mirabedi Anousheh S, Delate Thomas, Daida Yihe, Williams Andrew E, Alexander Gwen L, McCarty Catherine A, Honda Stacey, Kushi Lawrence H, Goddard Katrina A B
Abstract excerpt
BACKGROUND: In metastatic colorectal cancer (mCRC), mutations in the KRAS gene predict poor response to EGF receptor (EGFR) inhibitors. Clinical treatment guidelines now recommend KRAS testing if EGFR inhibitors are considered. Our study investigates the clinical uptake and utilization of KRAS testing. METHODS: We included 1,188 patients with mCRCs diagnosed from 2004 to 2009, from seven integrated health care...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.